In general I would agree with most of your points and I think now Zenith is well positioned with most if not all trials being shared cost or paid for by another party. I too would like the questions you asked answered, I asked similar questions in typed format last time but most were not addressed.  Last time he did say he felt "we’re in a strong position to unlock some significant value for shareholders in the near future" I would like him to flesh out the detail wrt time on that at the AGM, that being said as far as timelines go we will probably hear the same old load of bs that has very little to do with reality. 

You mention Nasdaq, I would agree that it is no place for Zenith, management is way too poor and unsophisticated to be successful there IMO. I think success there is more dependent on good management and their relationships in the US financial community than it is on where the company is founded/domiciled, Abcellera and Trillium being two Canadian biotechs who did just fine on Q. JMO